Relay Therapeutics And Pfizer Collaborate On Clinical Trial To Evaluate Atirmociclib In Combination With RLY-2608

6/5/24 4:31:34 PM ET

$PFE

$RLAY

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $PFE alert in real time by email

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NYSE:PFE) to evaluate atirmociclib, Pfizer's investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

Get the next $PFE alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$PFE
$RLAY

Company	Date	Price Target	Rating	Analyst
Pfizer Inc. $PFE	2/20/2026	$25.00	Underweight	Barclays
Pfizer Inc. $PFE	2/12/2026	$27.00	Outperform → Neutral	Daiwa Securities
Relay Therapeutics Inc. $RLAY	1/26/2026	$14.00	Perform → Outperform	Oppenheimer
Pfizer Inc. $PFE	1/7/2026	$25.00	Neutral	UBS
Relay Therapeutics Inc. $RLAY	12/12/2025	$13.00	Equal Weight → Overweight	Wells Fargo
Pfizer Inc. $PFE	12/2/2025	$26.00	Neutral	Citigroup
Pfizer Inc. $PFE	11/13/2025	$30.00	Sector Outperform	Scotiabank
Relay Therapeutics Inc. $RLAY	9/4/2025	$15.00	Buy	Guggenheim

More analyst ratings

Relay Therapeutics And Pfizer Collaborate On Clinical Trial To Evaluate Atirmociclib In Combination With RLY-2608

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $PFE$RLAY

Relay Therapeutics And Pfizer Collaborate On Clinical Trial To Evaluate Atirmociclib In Combination With RLY-2608

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $PFE$RLAY

$PFE$RLAY Insider Purchases

Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

$PFE$RLAY Press Releases

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

$PFE$RLAY SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.

SEC Form 13F-HR filed by Pfizer Inc.

$PFE$RLAY Analyst Ratings

Barclays initiated coverage on Pfizer with a new price target

Pfizer downgraded by Daiwa Securities with a new price target

Relay Therapeutics upgraded by Oppenheimer with a new price target

$PFE$RLAY FDA approvals

October 25, 2024 - FDA Roundup: October 25, 2024

FDA Approval for HYMPAVZI issued to PFIZER INC

October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

$PFE$RLAY Insider Trading

SEC Form 4 filed by Chairman & CEO Bourla Albert

President, R&D Boshoff Christoffel covered exercise/tax liability with 12,887 shares, decreasing direct ownership by 8% to 155,645 units (SEC Form 4)

President, R&D Bergstrom Donald A sold $166,677 worth of shares (21,581 units at $7.72), decreasing direct ownership by 5% to 420,047 units (SEC Form 4)

$PFE$RLAY Leadership Updates

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

$PFE$RLAY Financials

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

$PFE$RLAY Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

SEC Form SC 13G filed by Relay Therapeutics Inc.

Recent Analyst Ratings for
$PFE
$RLAY

Recent Analyst Ratings for
$PFE
$RLAY

$PFE
$RLAY
Insider Purchases

$PFE
$RLAY
Press Releases

$PFE
$RLAY
SEC Filings

$PFE
$RLAY
Analyst Ratings

$PFE
$RLAY
FDA approvals

$PFE
$RLAY
Insider Trading

$PFE
$RLAY
Leadership Updates

$PFE
$RLAY
Financials

$PFE
$RLAY
Large Ownership Changes